WASHINGTON, D.C. (January 28, 2003) — Media registration is now open for the Biotechnology Industry Organization’s (BIO) CEO & Investor Conference 2003, February 25-27 at the Waldorf-Astoria in New York City. The event will provide a forum where senior biotechnology executives, institutional investors, industry analysts, venture capitalists and investment bankers will have the opportunity to shape the future investment landscape of the biotechnology industry.
Seven investor sessions will focus on technology advancements including cancer and protein therapeutics, infectious diseases, and rheumatoid arthritis. Eight CEO roundtables will focus on the business side of biotechnology, including SEC rules, FDA reorganization, and intellectual property issues. In addition, more than 190 biotech companies were selected to present at the event.
Registration is complimentary for credentialed news media. Advance registration is available until February 14. To register, please visit www.bio.org. Only reporters and editors working full-time for print, or broadcast news organizations may register onsite with valid media credentials.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.